title: [Use of immunomodulators in the therapy of chronic hepatitis C: improving standard approach].
abstract: Results of a comparative study of the standard and an improved (triple) antiviral therapy in a group of 86 patients with chronic viral hepatitis C (1b genotype) with a period of infection up to five years are presented. The standard therapy consisted in the administration of concentrated alpha-interferon (Interal, Russia) and synthetic nucleozide ribavirin, while the improved (triple) therapy additionally included the administration of the interferon inducer cycloferon. The effectiveness of treatment using the improved scheme increased by 8.8%, the number of adverse drug reactions decreased more than three times, and morphological improvement was observed in 69.4-87.8% of patients. Modification of the standard treatment of hepatitis C improves the quality of life of hepatitis C patients.
authors.forename: M G
authors.initials: MG
authors.lastname: Romantsov
authors.forename: N V
authors.initials: NV
authors.lastname: Kremen'
authors.forename: T V
authors.initials: TV
authors.lastname: Sologub
mesh_terms: D000166:Acridines / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D011788:Quality of Life; D012254:Ribavirin / Q000008:administration & dosage
chemical_list: D000166:Acridines; D000998:Antiviral Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; D012254:Ribavirin; C026430:10-carboxymethyl-9-acridanone